Johanne I. Weberpals

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L. Coleman, Amit M. Oza, Domenica Lorusso et al. · The Lancet · 2017 · 1.7K citations · Full text

Medicine, Gynecology, Oncology +12

EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer

Alexandria Haslehurst, Madhuri Koti, Moyez Dharsee et al. · BMC Cancer · 2012 · 405 citations · Full text

Medicine, Cell Biology, Oncology +17

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial

Stéphanie Lheureux, Mihaela Cristea, Jeffrey P. Bruce et al. · The Lancet · 2021 · 211 citations · Full text

Medicine, Oncology, Pharmacology +10

Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus–Related Cervical Carcinoma

Stéphanie Lheureux, Marcus O. Butler, Blaise Clarke et al. · JAMA Oncology · 2017 · 162 citations · Full text

Medicine, Oncology, Pharmacology +17

Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial

Jonathan A. Ledermann, Amit M. Oza, Domenica Lorusso et al. · The Lancet Oncology · 2020 · 127 citations · Full text

Medicine, Oncology, Pharmacology +15